Natera Inc Revenue Growth Rates (NTRA), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Natera Inc   (NASDAQ: NTRA)
    Sector • Healthcare    Industry • Medical Laboratories
   Industry • Medical Laboratories
   Sector • Healthcare
 

NTRA's Revenue Growth by Quarter and Year

Natera Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/NTRA/growth
https://api.csimarket.com/api/v1/companies/NTRA/fundamentals
https://api.csimarket.com/api/v1/companies/NTRA/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery
Connect Your AI Assistant
How to Connect Your AI Assistant to CSIMarket MCP MCP Server
Access this full dataset via API
Free sample Full docs All endpoints
NTRA Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 793.98
2nd Quarter June 752.75
1st Quarter March 696.64
FY 2,243.37

NTRAs Annual Revenue
Natera Inc 's Revenue in the fiscal year 2025 $ 2,306.11 millions
Natera Inc 's Revenue in the fiscal year 2024 $ 1,696.91 millions
Natera Inc 's Revenue in the fiscal year 2023 $ 1,082.57 millions
Natera Inc 's Revenue in the fiscal year 2022 $ 820.22 millions
Natera Inc 's Revenue in the fiscal year 2021 $ 625.49 millions




NTRA Revenue third quarter 2026 Y/Y Growth Comment
Natera Inc achieved in the third quarter 2026, above Company average Revenue growth of 34.08% year on year, to $ 793.98 millions.

Looking into third quarter 2026 results within Medical Laboratories industry 7 other companies have achieved higher Revenue growth. While Natera Inc ' s Revenue rise of 34.08% ranks overall at the positon no. 612 in the third quarter 2026.


NTRA Revenue ( Y/Y Growth %) 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 34.08 %
2nd Quarter June 37.71 %
1st Quarter March 38.82 %
FY   -

Financial Statements
Natera Inc 's third quarter 2026 Revenue $ 793.98 millions NTRA's Income Statement
Natera Inc 's third quarter 2025 Revenue $ 592.18 millions Quarterly NTRA's Income Statement


NTRA Revenue (Quarter on Quarter Growth %)

 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 5.48 %
2nd Quarter June 8.05 %
1st Quarter March 4.68 %
FY (Year on Year)   -


Back to NTRA Growth rate Comparisons >> Back to NTRA Growth rate Comparisons >>


Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry #8
Healthcare Sector #143
Overall #612

Revenue Y/Y Growth Statistics
High Average Low
73.79 % 29.84 % -24.23 %
(Mar 31 2017)   (Dec 31 2017)
Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry #8
Healthcare Sector #143
Overall #612
Revenue Y/Y Growth Statistics
High Average Low
73.79 % 29.84 % -24.23 %
(Mar 31 2017)   (Dec 31 2017)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Natera Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
35.54 % 7.45 % -16.02 %
(Mar 31 2021)  


NTRA's III. Quarter Q/Q Revenue Comment
Natera Inc achieved in the III. Quarter 2026 below company average Revenue increase of 5.48% quarter on quarter, to $ 793.98 millions.

Within Medical Laboratories industry 7 other companies have achieved higher Revenue quarter on quarter growth. While Natera Inc 's Revenue growth quarter on quarter, overall rank is 896.


Revenue Q/Q Growth Company Ranking
Within: No.
Medical Laboratories Industry #8
Healthcare Sector #137
Overall #896
Revenue Q/Q Growth Company Ranking
Within: No.
Medical Laboratories Industry #8
Healthcare Sector #137
Overall #896
Revenue Q/Q Growth Statistics
High Average Low
35.54 % 7.45 % -16.02 %
(Mar 31 2021)  


NTRA's III. Quarter Q/Q Revenue Comment
Natera Inc achieved in the III. Quarter 2026 below company average Revenue increase of 5.48% quarter on quarter, to $ 793.98 millions.

Within Medical Laboratories industry 7 other companies have achieved higher Revenue quarter on quarter growth. While Natera Inc 's Revenue growth quarter on quarter, overall rank is 896.


Natera Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending (Mar 31 2026) 12 Months Ending (Dec 31 2025) 12 Months Ending (Sep 30 2025) 12 Months Ending (Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 2,707.08
Y / Y Revenue Growth (TTM) 37.82 %
Year on Year Revenue Growth Overall Ranking # 295
Seqeuential Revenue Change (TTM) 8.24 %
Seq. Revenue Growth (TTM) Overall Ranking # 1612


Cumulative Revenue growth Comment
Although Natera Inc 's Annual Revenue growth year on year were below company's average 55.32% , Revenue announced in the Jun 30 2026 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 37.82% year on year, from 36.59% in Mar 31 2026.

In the Healthcare sector 84 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 116 to 295.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry # 17
Healthcare Sector # 85
Overall # 295

Revenue TTM Y/Y Growth Statistics
High Average Low
410.42 %
 55.32 %
-36.26 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 17
Sector # 262
S&P 500 # 1612
Cumulative Revenue growth Comment
Although Natera Inc 's Annual Revenue growth year on year were below company's average 55.32% , Revenue announced in the Jun 30 2026 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 37.82% year on year, from 36.59% in Mar 31 2026.

In the Healthcare sector 84 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 116 to 295.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry # 17
Healthcare Sector # 85
Overall # 295

Revenue TTM Y/Y Growth Statistics
High Average Low
410.42 %
55.32 %
-36.26 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 17
Sector # 262
S&P 500 # 1612




Other Revenue Growth
Medical Laboratories Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
NTRA's Revenue Growth Ratio versus Medical Laboratories Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue increase for the quarter ending Sep 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2026
Glaukos Corp59.02%$ 59.021 millions
X4 Pharmaceuticals Inc58.64%$ 58.640 millions
Kiniksa Pharmaceuticals International Plc58.12%$ 58.121 millions
Envoy Medical Inc 57.14%$ 57.143 millions
Humacyte Inc 55.21%$ 55.208 millions
Butterfly Network Inc 53.45%$ 53.453 millions
Avita Medical Inc 53.05%$ 53.054 millions
Immunitybio inc 52.34%$ 52.338 millions
Axsome Therapeutics Inc 51.87%$ 51.873 millions
Innovative Eyewear Inc 51.12%$ 51.123 millions
Strata Critical Medical Inc 50.27%$ 50.272 millions
Madrigal Pharmaceuticals Inc 50.13%$ 50.127 millions
Immucell Corporation49.91%$ 49.912 millions
Hims and Hers Health Inc 48.88%$ 48.877 millions
Maxcyte inc 48.66%$ 48.660 millions
Billiontoone Inc 47.43%$ 47.431 millions
Arcutis Biotherapeutics Inc 45.05%$ 45.052 millions
Zevra Therapeutics Inc 44.86%$ 44.864 millions
Xeris Biopharma Holdings Inc 44.16%$ 44.158 millions
Nephros Inc 43.60%$ 43.602 millions
Cardiff Oncology Inc 42.50%$ 42.500 millions
Neurocrine Biosciences Inc 41.24%$ 41.238 millions
Transmedics Group Inc 41.15%$ 41.149 millions
Uniqure N v 40.39%$ 40.394 millions
Harrow Inc 40.00%$ 40.001 millions
Mirum Pharmaceuticals Inc 39.63%$ 39.629 millions
Caredx Inc 39.29%$ 39.285 millions
Halozyme Therapeutics Inc 39.15%$ 39.154 millions
Eli Lilly And Company38.61%$ 38.613 millions
Myomo Inc 37.42%$ 37.416 millions


About Natera Inc Revenue Growth Rates (NTRA), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Natera Inc (CIK 1604821).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001628280-26-071145
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Natera Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.